Status: Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
Participants needed: 600
Trial details
Phase: Phase 2Age: 40-85Biological sex: AllType: InterventionalSponsor: Expedition Therapeutics, IncUpdated: Aug 7, 2026Locations: 20
Eligibility criteria
Provided written informed consent for the study [+14]
COPD exacerbation within the 4 weeks prior to randomization. [+20]